 GSKs experimental fluoroquinolone antibiotic gepotidacin ended its trial early due to its success in treating uncomplicated urinary tract infections UTIs, the pharma announced this week. Deutsche Bank says that while a new antibiotic wont set investors pulses racing, it might be a nice add-on. 